Insmed Provides Business Update at 42nd Annual J.P. Morgan Healthcare Conference
—ARIKAYCE® (amikacin liposome inhalation suspension) Delivers Full-Year 2023 Revenues Exceeding the Upper End of Guidance Range with Unaudited Global Net Product Sales of Approximately $305.2 Million—
Related news for (INSM)
- Insmed Announces Pricing of $750 Million Public Offering of Common Stock
- Insmed Announces Proposed $650 Million Public Offering of Common Stock
- Insmed Announces Positive Topline Results from Phase 2b Study of Treprostinil Palmitil Inhalation Powder (TPIP) as Once-Daily Therapy in Patients with Pulmonary Arterial Hypertension
- Insmed Reports First-Quarter 2025 Financial Results and Provides Business Update
- Insmed Announces Redemption of all $569.5 Million of Remaining Outstanding 0.75% Convertible Senior Notes Due 2028